EU OKs Mass. plant for Genzyme's Fabry disease drug

01/18/2012 | Reuters

The European Medicines Agency is permitting Sanofi division Genzyme to produce Fabry disease medicine Fabrazyme at a Framingham, Mass., facility. The approval "represents an important milestone in our manufacturing recovery and a path toward unconstrained supply for all patients," said Genzyme CEO and President David Meeker. The biotech firm still awaits FDA approval.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID